Colin Goddard takes over as non-executive chairman of Mission Therapeutics Ltd on 1 January 2017 as the company advances its portfolio of enzyme inhibitors targeting difficult-to-treat cancers. Dr Goddard, who has been a non-executive director since July 2015, will replace Michael Moore, the company’s founding chair.
Dr Goddard is currently chairman and CEO of BlinkBio Inc and a director of Endocyte Inc. Previously, he served as CEO of OSI Pharmaceuticals, which was acquired by Astellas Pharma Inc in 2010 for $4 billion.
Dr Goddard holds a PhD in cancer pharmacology from the University of Aston in Birmingham, UK. He worked at the US National Cancer Institute before joining OSI.
Mission Therapeutics announced the appointment on 5 December 2016.
Copyright 2016 Evernow Publishing Ltd